DSM Signs Contract with QRxPharma to Produce MoxDuo® Capsules
PARSIPPANY, N.J., Dec. 13, 2011 /PRNewswire/ -- DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V. (DSM KON: NYSE/Euronext), today announces the signing of a manufacturing and supply agreement with QRxPharma, Inc., based in Bedminster, New Jersey, USA, for the production of their novel pain management product MoxDuo® capsules to supply the U.S. market through 2015.
The agreement covers the production of MoxDuo® Capsules, an immediate-release Dual Opioid® pain therapy comprised of a patented 3:2 fixed ratio combination of morphine and oxycodone, by DSM. DSM will supply commercial volumes upon marketing approval. DSM operates a 1.5 million square foot finished dosage facility in Greenville, North Carolina, USA, for oral solid dosage, as well as liquid steriles, and holds a range of regulatory approvals including the production of scheduled drugs.
Hans Engels , President, DSM Pharmaceuticals, Inc. stated: "We are honored to be working with QRxPharma for the supply of this product. Combining the expertise of QRx in developing innovative medicines with DSM's strength in Good Manufacturing Practices (GMP), enforced by the U.S. Food and Drug Administration, and supply chain management will provide a superior solution for patients."
QRxPharma, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders.
"We have had a very productive relationship with DSM over the years as we evolved MoxDuo® Capsules through to New Drug Application (NDA) filing, and we are now looking forward to launching our product into the acute pain marketplace in the US in 2012 with the manufacturing support of DSM," said Dr. John Holaday , Managing Director and Chief Executive Officer, QRxPharma.
No financial details are disclosed.
MoxDuo® is a registered trademark of QRxPharma, Ltd.
Dual Opioid® is a registered trademark of QRxPharma, Ltd.
QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy that focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to co-promote its products in the US and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, immediate release MoxDuo, now awaits approval by the US Food and Drug Administration (FDA). Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MoxDuo, as well as other pipeline technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.
DSM – Bright Science. Brighter Living .™
DSM Pharmaceutical Products is a Business Group of Royal DSM N.V. is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about euro 9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsmpharmaceuticalproducts.com and www.dsm.com.
This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.
For more information:
SOURCE DSM Pharmaceutical Products
More by this Source
DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
Apr 22, 2013, 02:00 ET
DSM signs Master Supply Agreement with Eisai Inc.
Mar 05, 2013, 02:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.